Check out the latest Prokaryotics buzz below.


Prokaryotics Receives $2.3 Million SBIR Grant Supporting A Second Novel Antibiotic Program

Union, NJ -- September 13, 2018 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded its second Small Business Innovation Research Grant (SBIR) valued at up to $2.3 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.


Prokaryotics Receives $2.5 Million SBIR Grant to Support Novel Antibiotic Program

Union, NJ -- March 08, 2018 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded a Small Business Innovation Grant (SBIR) valued at up to $2.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.


Media Coverage

Union, NJ -- January 30, 2018 -- We appreciate Merck's support and, with our collaborators, are committed to taking on the global challenge of antibiotic resistance. Please click the link for details. Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D.


Prokaryotics Announces Licensing Agreement with Merck

Union, NJ -- January 25, 2018 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into a licensing agreement with Merck, known as MSD outside the United States and Canada. Please click here for more details.


Novel Antibiotic Discovery Startup Commences Operations

Union, NJ -- January, 2017 -- Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs.